ClinicalTrials.gg
CompletedNCT01474590POWERUpdated Feb 18, 2021Results posted

Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne

A Phase 3 interventional study of Epiduo/Tactuo and vehicle gel in Acne, sponsored by Galderma R&D. Completed at 26 sites in Canada. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
12 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing doxycycline in Acne Vulgaris — 2 open to participants now, 3 under way, none of them phase 3. Doxycycline · Acne Vulgaris.

Enrollment
Largest of 12
266 · median 47
Started
2011
the only one that year
Phase 3
Only one
of the 12
Registered
6th of 12
by date
Lead sponsor
1 of 12
Galderma R&D

Among the 12 studies testing doxycycline in Acne Vulgaris, this one has the largest enrollment, is the only one that started in 2011, is the only one in phase 3, and was the 6th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

2 of the 12 studies testing doxycycline in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About doxycycline

Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing doxycycline in Acne Vulgaris, or all of them as a file.
02

Study summary

Non-inferiority, randomized, controlled, multi-center, investigator-blind, parallel-group comparison study in subjects with severe acne vulgaris on the face.

03

Conditions studied

  • Acne

Browse trials for

04

Who can participate

Ages eligible
12 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subject of any race, aged 12 to 35 years inclusive
  2. Subject weighing between 50 and 110 kg
  3. Subject with severe acne (IGA at least 4), which in the opinion of the investigator is appropriate for treatment with oral isotretinoin (severe nodular acne, severe inflammatory acne, recalcitrant acne; all unresponsive to conventional therapies)
  4. Subject with at least 5 nodules on the face

Exclusion criteria

Exclusion Criteria:

  1. Subject with clinically abnormal results to blood testings performed at screening
  2. Subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), pyoderma faciale, sinus tracks
  3. Female subject who is pregnant, nursing or planning a pregnancy during the study
  4. Subject with known history of hepatic and/or renal insufficiency, to be confirmed by blood testings
  5. Subject with known metabolic or structural bone disease (for 12-17 years old population)
  6. Subject with bowel disease and/or with hypervitaminosis A
  7. Subject who presents with treated or untreated depression or has a history of depression including a family history of major depression
  8. Subject with a from baseline for topical treatment on the face less than : , antibiotics, antibacterials, antiseptics, retinoids, other anti-inflammatory drugs or other acne treatments (2 weeks); Cosmetic procedures (1 week); Photodynamic therapy and laser therapy for acne (3 months)
  9. Subject with a wash-out period from baseline for systemic treatment less than: Corticosteroids, antibiotics (4 weeks),Progesterone for (3 months); Spironolactone(3 months); Other acne treatments (6 months);Cyproterone acetate(6 months)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
266 participants (actual)

Study arms

  • Experimental
    Epiduo/Tactuo + doxycycline 200mg

    Drug: Epiduo/Tactuo · Drug: doxycycline 200mg

  • Active comparator
    Isotretinoin + vehicle gel

    Other: vehicle gel · Drug: Isotretinoin

Interventions

  • DrugEpiduo/Tactuo

    topical to the face, once daily in the evening

  • Othervehicle gel

    topical to the face, once daily in the evening

  • oral, 2 capsules once daily in the morning with aglass of water and with food

  • oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.

06

What researchers measure

Primary outcomes

  1. The Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements

    Overall success is reached when the 2 following criteria are fulfilled : 1. Overall efficacy: reduction of at least 75% of number of nodules at the end of treatment 2. Safe treatment: Absence of any listed safety issues

    Time frame: 20 weeks

07

Results

Posted Aug 28, 2017

Participant flow

Participant flow — Overall Study
MilestoneEpiduo/Tactuo + Doxycycline 200mgIsotretinoin + Vehicle Gel
Started133133
Completed105116
Not completed2817

Outcome measures

PrimaryThe Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements

Overall success is reached when the 2 following criteria are fulfilled : 1. Overall efficacy: reduction of at least 75% of number of nodules at the end of treatment 2. Safe treatment: Absence of any listed safety issues

Time frame:
20 weeks
Reported as:
Number · count of participants
The Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements
count of participantsEpiduo/Tactuo + Doxycycline 200mgIsotretinoin + Vehicle Gel
The Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements8573

Adverse events

Collected over 20 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epiduo/Tactuo + Doxycycline 200mg—0/133 (0%)25/133 (18.8%)
Isotretinoin + Vehicle Gel—1/133 (0.8%)66/133 (49.6%)
Most frequent serious events
Most frequent serious events
EventEpiduo/Tactuo + Doxycycline 200mgIsotretinoin + Vehicle Gel
Stevens-Johnson syndromeSkin and subcutaneous tissue disorders0/1331/133
Most frequent other events
Most frequent other events
EventEpiduo/Tactuo + Doxycycline 200mgIsotretinoin + Vehicle Gel
lip dryGastrointestinal disorders9/13366/133
dry skinSkin and subcutaneous tissue disorders25/13343/133
cheilitisGastrointestinal disorders2/13332/133
naospharyngitisInfections and infestations15/13314/133
skin irritationSkin and subcutaneous tissue disorders14/1337/133
nauseaGastrointestinal disorders14/1335/133
UPTRI (Upper Tract Respiratory Infection)Infections and infestations9/13313/133
headacheNervous system disorders12/13311/133
vomitingGastrointestinal disorders12/1332/133

Baseline characteristics

Age, Continuous
Age, Continuous(years)Epiduo/Tactuo + Doxycycline 200mgIsotretinoin + Vehicle GelTotal
Mean19.5 ± 5.019.3 ± 4.519.4 ± 4.8
Sex: Female, Male
Sex: Female, Male(Participants)Epiduo/Tactuo + Doxycycline 200mgIsotretinoin + Vehicle GelTotal
Female182139
Male115112227
Region of Enrollment
Region of Enrollment(count of participants)Epiduo/Tactuo + Doxycycline 200mgIsotretinoin + Vehicle GelTotal
Canada133133266
IGA
IGA(count of participants)Epiduo/Tactuo + Doxycycline 200mgIsotretinoin + Vehicle GelTotal
4118115233
5151833
nodule counts
nodule counts(nodules)Epiduo/Tactuo + Doxycycline 200mgIsotretinoin + Vehicle GelTotal
Mean8.0 ± 3.67.6 ± 2.57.8 ± 3.1
08

Study locations

26 sites
  • Galderma investigational site
    Ajax, Canada
  • Galderma investigational site
    Barrie, Canada
  • Galderma investigational site
    Calgary, Canada
  • Galderma investigational site
    Edmonton, Canada
  • Galderma investigational site
    Halifax, Canada
  • Galderma investigational site
    Hamilton, Canada
  • Galderma investigational site
    Markham, Canada
  • Galderma investigational site
    Montreal, Canada
  • Galderma investigational site
    Newmarket, Canada
  • Galderma investigational site
    Oakville, Canada
  • Galderma investigational site
    Oshawa, Canada
  • Galderma investigational site
    Peterborough, Canada
  • Galderma investigational site
    Quebec city, Canada
  • Galderma investigational site
    Richmond Hill, Canada
  • Galderma investigational site
    Saint-Hyacinthe, Canada
  • Galderma investigational site
    Saint-John's, Canada
  • Galderma investigational site
    Saskatoon, Canada
  • Galderma investigational site
    St John's, Canada
  • Galderma investigational site
    Sudbury, Canada
  • Galderma investigational site
    Surrey, Canada
  • Galderma investigational site
    Toronto, Canada
  • Galderma investigational site
    Vancouver, Canada
  • Galderma investigational site
    Waterloo, Canada
  • Galderma investigational site
    Windsor, Canada
  • Galderma investigational site
    Winnipeg, Canada
  • Galderma investigational site
    Woodbridge, Canada
09

References and documents

Publications

  • Tan J, Humphrey S, Vender R, Barankin B, Gooderham M, Kerrouche N, Audibert F, Lynde C; POWER study group. A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin. Br J Dermatol. 2014 Dec;171(6):1508-16. doi: 10.1111/bjd.13191. Epub 2014 Oct 28. PubMed 24934963 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jul 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2011
First posted
Nov 18, 2011
Start
Nov 2011
Primary completionActual
Jul 2013
CompletionActual
Aug 2013
Results first posted
Aug 28, 2017
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01474590
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Nov 18, 2011
Start date
Nov 2011
Primary completion
Jul 2013
Completion
Aug 2013
Results posted
Aug 28, 2017
Last update
Feb 18, 2021

Study contacts

Jerry Tan
principal investigator · Windsor Clinical Research Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxycycline

Start the discussion